Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA accepts application for new Sanofi MS drug

By Drug Discovery Trends Editor | January 28, 2013

French drugmaker Sanofi said Monday that the Food and Drug Administration will review its experimental multiple sclerosis treatment Lemtrada.

Genzyme, Sanofi’s U.S. biotech business, said the FDA will conduct a standard 10-month review and will make a decision on the drug in late 2013. Sanofi wants to market Lemtrada as a treatment for relapsing multiple sclerosis. German drugmaker Bayer will have an option to help market the drug in the U.S. if it is approved.

Genzyme filed for marketing approval of Lemtrada in June, but the FDA refused the application because it wanted Genzyme to make changes to its application. European Union regulators are also reviewing the drug.

Sanofi also gave an update on early sales of Aubagio, an MS drug that was approved in September 2012 and launched in October. The company said more than 80 percent of U.S. multiple sclerosis specialists have written a prescription for the drug. About half of the patients who are taking Aubagio were most recently treated with Teva Pharmaceutical Industries Ltd.’s drug Copaxone or Biogen Idec Inc.’s Avonex. About 20 percent of patients hadn’t been treated before.

U.S shares of Sanofi fell 17 cents to $49.10 in morning trading.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE